丹诺医药
TENNOR THERAPEUTICS

TenNor Therapeutics (Suzhou) Limited
丹諾醫藥（蘇州）股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock code: 6872)

(1) FORMULATION OF THE 2026 H SHARE AWARD SCHEME; AND (2) AMENDMENTS TO THE ARTICLES OF ASSOCIATION

The board of directors (the "**Board**") of TenNor Therapeutics (Suzhou) Limited (the "**Company**", together with its subsidiaries, the "**Group**") hereby announces that on 21 September 2026, the Board resolved to formulate the 2026 H share award scheme (the "**H Share Scheme**") and to amend the Articles of Association of TenNor Therapeutics (Suzhou) Limited (the "**Articles of Association**"). The H Share Scheme and the amended Articles of Association shall become effective upon consideration and approval by the shareholders of the Company at the extraordinary general meeting to be convened by the Company (the "**EGM**").

FORMULATION OF THE H SHARE SCHEME

In order to further establish and improve a long-term incentive mechanism, attract and retain outstanding talents, fully mobilize the enthusiasm and creativity of employees, enhance employee cohesion and the core competitiveness of the Company, and thereby bring continuous and growing investment returns to investors, effectively aligning the interests of the shareholders of the Company and the Company with the personal interests of the grantees, and promoting the long-term, continuous and healthy development of the Company, the Board has agreed to formulate the H Share Scheme.

Eligible participants of the H Share Scheme include any full-time employees of any member company of the Group, including directors, senior management, key team members and other employees. The Board or its authorized persons may appoint any eligible participant as the selected participant of the relevant scheme from time to time.

Under the H Share Scheme, the existing H shares of the Company will be granted to the grantees of incentive shares as the restricted shares. The Company will, as the principal, enter into a trust deed with the trustee, pursuant to which, a trust will be established for the purpose of the H Share Scheme. Subject to the compliance with the trust deed and upon the instruction of the Company, the trustee will complete the purchase of relevant H shares under the H Share Scheme via market transactions. The source of funds for purchasing the award shares is the internal funds of the Company. The limit for award shares to be granted under the H Share Scheme shall be 5% of the total number of shares of the Company as at the adoption date of the H Share Scheme.

The H Share Scheme shall have an award term of 10 years from the adoption date (the "**Award Term**"), after expiry of the Award Term, no awards shall be granted, but the H Share Scheme shall continue to be extended until the vesting of such award shares takes effect, so long as there are any award shares granted but not vested before the expiry of the H Share Scheme.

The H Share Scheme does not involve the grant of new shares of the Company. However, the H Share Scheme constitutes a share scheme funded by existing shares under Chapter 17 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**"), and is subject to the applicable disclosure requirements under Rule 17.12 of the Listing Rules.

AMENDMENTS TO THE ARTICLES OF ASSOCIATION

For the purposes of the industrial and commercial registration requirements on the Company, the Board has resolved to amend the Articles of Association. The amended Articles of Association shall become effective upon consideration and approval by the shareholders of the Company at the EGM. Details of the amendments to the Articles of Association are set out as follows:

Before Amendments	**After Amendments**
Article 6 Prior to the issuance of H-shares, the company's registered capital is RMB43,472,926.	**Article 6** ~~**Prior to the issuance of H-shares,**~~ **T**he company's registered capital is RMB~~**43,472,926**~~**52,328,926**.
Article 8 The Chairman of the Board is the legal representative of the Company. If the Chairman resigns, he/she shall be deemed to have resigned as the legal representative. If the legal representative resigns, the Company shall appoint a new legal representative within 30 days from the date of resignation.	**Article 8** ~~**The Chairman of the Board is**~~ **T**he legal representative of the Company **shall be a director who performs the company affairs on behalf of the Company**. **The Chairman of the Board shall be the director who performs the company affairs on behalf of the Company.** If the **director** ~~**Chairman**~~ resigns, he/she shall be deemed to have resigned as the legal representative. If the legal representative resigns, the Company shall appoint a new legal representative within 30 days from the date of resignation.

A circular containing, among other things, details of the resolutions to be proposed for consideration at the EGM, together with the notice of the EGM, will be despatched in due course.

By order of the Board
TenNor Therapeutics (Suzhou) Limited
Dr. Ma Zhenkun
Chairman of the Board, Executive Director,
Chief Executive Officer and General Manager

Hong Kong, 21 September 2026

As at the date of this announcement, the Board comprises: (i) Dr. Ma Zhenkun as an executive Director; (ii) Dr. Song Gaoguang as a non-executive Director; and (iii) Mr. Lee Wai Kong, Albert, Dr. Ni Lin and Dr. Li Leping as independent non-executive Directors.